PHARMACEUTICAL DOSAGE FORMS CONTAINING SODIUM-1-[6-(MORPHOLIN-4-YL)PYRIMIDIN-4-YL]-4-(1H-1,2,3-TRIAZOL-1-YL)-1H-PYRAZOL-5-OLATE

The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-( 1 H-1,2,3-triazol-1-yl)-l H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for...

Full description

Saved in:
Bibliographic Details
Main Authors FORMELL, Michael, NEUMANN, Heike, WINTER, Gabriele, BENKE, Klaus
Format Patent
LanguageEnglish
Published 06.10.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-( 1 H-1,2,3-triazol-1-yl)-l H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.
Bibliography:Application Number: TN20160000135